Drug Trial Radar · NCT05282030
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Mar 10, 2022
Primary completion
Aug 2, 2022
Study completion Aug 2, 2022
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this parallel group, Phase 1, open-label, 2-arm study is to assess the effect of severe (Part A) and moderate (Part B, conditional) renal impairment (RI) on pharmacokinetics (PK), safety and tolerability of tolebrutinib tablets compared with normal renal function, in male and female participants aged 18 to 79 years.
Conditions
- Renal Impairment
Interventions
tolebrutinibDrug
Pharmaceutical form: Film-coated tablets Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of PK parameters Tolebrutinib: AUCTime frame: From Day 1 to Day 4
- Assessment of PK parameters M2: AUCTime frame: From Day 1 to Day 4
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami Site Number : 8400002
Miami, Florida
Nucleus Network Site Number : 8400001
Saint Paul, Minnesota
Volunteer Research Group-NOCCR Site Number : 8400003
Knoxville, Tennessee
Investigational Site Number : 2760001
Kiel, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.